VIS viva intranasal contra la influenza

Influenza (Flu) Vaccine (Live, Intranasal): What You Need to Know

Why get vaccinated?

Influenza vaccine can prevent influenza (flu).

Flu is a contagious disease that spreads around the United States every year, usually between October and May. Anyone can get the flu, but it is more dangerous for some people. Infants and young children, people 65 years of age and older, pregnant women, and people with certain health conditions or a weakened immune system are at greatest risk of flu complications.

Neumonía, bronquitis, sinusitis e infecciones del oído son algunos ejemplos de complicaciones relacionadas con la influenza. If you have a medical condition, such as heart disease, cancer or diabetes, flu can make it worse.

Flu can cause fever and chills, sore throat, muscle aches, fatigue, cough, headache, and runny or stuffy nose. Algunas personas pueden tener vómitos y diarrea, aunque esto es más común en los niños que en los adultos.

Each year thousands of people in the United States die from flu, and many more are hospitalized. Flu vaccine prevents millions of illnesses and flu-related visits to the doctor each year.

Live, attenuated influenza vaccine

CDC recommends everyone 6 months of age and older get vaccinated every flu season. Children 6 months through 8 years of age may need 2 doses during a single flu season.  Everyone else needs only 1 dose each flu season.

Live, attenuated influenza vaccine (called LAIV) is a nasal spray vaccine that may be given to non-pregnant people 2 through 49 years of age.

It takes about 2 weeks for protection to develop after vaccination.

Existen muchos virus de la influenza y cambian constantemente. Cada año se fabrica una nueva vacuna contra la influenza que protege contra tres o cuatro virus que posiblemente sean los responsables de causar la enfermedad en la próxima temporada de influenza. Incluso cuando la vacuna no se corresponde con estos virus con exactitud, igual puede brindar algún tipo de protección.

La vacuna contra la influenza no causa la influenza.

La vacuna contra la influenza puede ser administrada al mismo tiempo que otras vacunas.

Talk with your health care provider

Cuéntele a su proveedor si la persona que recibe la vacuna:

  • Is younger than 2 years or older than 49 years of age.
  • Is pregnant.
  • Has had an allergic reaction after a previous dose of influenza vaccine, or has any severe, life-threatening allergies.
  • Is a child or adolescent 2 through 17 years of age who is receiving aspirin or aspirin-containing products.
  • Has a weakened immune system.
  • Is a child 2 through 4 years old who has asthma or a history of wheezing in the past 12 months.
  • Has taken influenza antiviral medication in the previous 48 hours.
  • Cares for severely immunocompromised persons who require a protected environment.
  • Is 5 years or older and has asthma.
  • Has other underlying medical conditions that can put people at higher risk of serious flu complications (such as lung disease, heart disease, kidney disease, kidney or liver disorders, neurologic or neuromuscular or metabolic disorders).
  • Has had Guillain-Barré Syndrome within 6 weeks after a previous dose of influenza vaccine.

En algunos casos, su proveedor de atención médica puede decidir posponer la vacunación contra la influenza para una futura consulta.

For some patients, a different type of influenza vaccine (inactivated or recombinant influenza vaccine) might be more appropriate than live, attenuated influenza vaccine.

Las personas con enfermedades menores, como un resfriado, pueden vacunarse. Por lo general, las personas con una enfermedad moderada o grave deberían esperar hasta su recuperación para recibir la vacuna contra la influenza.

Su proveedor de atención médica puede brindarle más información.

Risks of a vaccine reaction
  • Runny nose or nasal congestion, wheezing and headache can happen after LAIV.
  • Vomiting, muscle aches, fever, sore throat and cough are other possible side effects.

Si ocurren estos problemas, por lo general comienzan poco después de la vacunación, son leves y duran poco tiempo.

Como con cualquier medicamento, existe una posibilidad muy remota de que una vacuna cause una reacción alérgica severa, alguna otra lesión grave o incluso la muerte.

What if there is a serious problem?

An allergic reaction could occur after the vaccinated person leaves the clinic. If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call 9-1-1 and get the person to the nearest hospital.

For other signs that concern you, call your health care provider.

Adverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS). Your health care provider will usually file this report, or you can do it yourself. Visite los sitio web de VAERSícono de sitio externo o llame al 1-800-822-7967VAERS is only for reporting reactions, and VAERS staff do not give medical advice.

Programa nacional de compensación por lesiones causadas por vacunas

El Programa nacional de compensación por lesiones causadas por vacunas (VICP) es un programa federal que fue creado con la finalidad de compensar a las personas que quizás sufrieron lesiones a causa de ciertas vacunas. Visite los VICP websiteícono de sitio externo or call 1-800-338-2382 to learn about the program and about filing a claim. There is a time limit to file a claim for compensation.

¿Cómo puedo conocer más?

Many Vaccine Information Statements are available in español and other languages. Vea http://www.immunize.org/visícono de sitio externo.

Hojas de información sobre vacunas están disponibles en español y en muchos otros idiomas. Visite http://www.immunize.org/vis/vis_spanish.aspícono de sitio externo

Vaccine Information Statement (Interim)
Live Attenuated Influenza Vaccine (8/15/2019)
42 U.S.C. §300aa-26

Departamento de Salud y Servicios Humanos
Centros para el Control y la Prevención de Enfermedades

Office Use Only

Varicella barcode
Esta página fue revisada el 15 de agosto del 2019
Fuente del contenido:

Centro Nacional de Vacunación y Enfermedades Respiratorias
Issue date of VIS: August 7, 2015